Esperoct market seen growing on hemophilia A demand through 2030

The Business Research Company says the global Esperoct market is set to expand through 2035, driven by rising hemophilia A diagnoses, broader use of extended half-life therapies and more homecare treatment. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Esperoct is positioned as a longer-acting treatment option for hemophilia A, which can reduce infusion frequency and improve day-to-day convenience for patients. - The market outlook reflects broader demand for advanced bleeding-disorder therapies, plus growing healthcare spending and rare-disease support.

What happened: - The Business Research Company published its Esperoct Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 3, 2026. - The report says the Esperoct market is gaining attention as hemophilia A treatment options continue to evolve. - The company released a free sample of the report and a full market report.

The details: - Esperoct, also called efanesoctocog alfa, is a long-acting recombinant factor VIII therapy for hemophilia A. - The therapy replaces deficient clotting factor VIII to help prevent bleeding episodes. - The extended formulation is designed to require fewer infusions than older factor VIII treatments. - Historical market growth was supported by the high bleeding risk in hemophilia A, frequent factor VIII infusion needs, progress in recombinant clotting factors, hospital-centered hemophilia care, and wider awareness of prophylaxis. - Forecast growth is tied to wider use of extended half-life therapies, adoption of homecare treatment models, higher hemophilia diagnosis rates, better patient adherence, and supportive rare-disease reimbursement policies. - The report points to rising use of long-acting clotting factor treatments, a shift toward prophylactic care, fewer infusion sessions, better quality of life, and broader home infusion programs. - Pfizer reported that the hemophilia A and B patient population in the U.K. exceeded 11,800 people in 2023/2024. - The Health Foundation in the U.K. said planned healthcare spending will rise from about $221.1 billion (£177.9 billion) to $237.4 billion (£190.1 billion) in 2024/25, with further growth to $250.1 billion (£200.5 billion) projected for 2025/26. - In 2025, North America held the largest share of the Esperoct market. - Asia-Pacific is expected to be the fastest-growing region over the coming years. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Between the lines: - The forecast is less about a single drug and more about a shift in hemophilia care toward longer-acting therapies and treatment at home. - Stronger reimbursement and healthcare investment can make premium specialty therapies easier to adopt, which supports market expansion. - The regional split suggests mature markets are leading current sales, while emerging markets may drive the next phase of growth.

What's next: - The report expects continued market gains through the forecast period as diagnosis, access and home-based care expand. - The fastest growth is likely to come from regions and health systems that are still broadening access to advanced hemophilia treatment. - The Business Research Company says it will continue updating forecasts, scoring tools and trend analysis across its market reports.